Kossoy George, Avinoach Ilana, Zusman Itshak, Scheider David P, Ben-Hur Herzl, Elhayany Asher
Laboratory of Experimental Oncology, Koret School of Veterinary Medicine, Faculty of Agricultural, Food and Environmental Quality Sciences, The Hebrew University of Jerusalem, PO Box 12, Rehovot 76100, Israel.
Oncol Rep. 2004 Feb;11(2):487-91.
This study examined whether the soluble 66- and 51 kDa tumor-associated antigens (sTAA), isolated from the serum of breast cancer patients, possess specific suppressive effects on chemically-induced rat mammary tumorigenesis in comparison to commercial human albumin. Dimethylbenzanthracene (DMBA, 10 mg/rat, 2 administrations) was used to induce mammary tumors in 8-week-old Sprague Dawley rats. After the appearance of many large tumors, preparations of sTAA (50-60 micro g/rat in 0.5 ml sterile PBS) or commercial human albumin (HA, in the same doses as sTAA) were administered weekly, for 10-14 more weeks. The following groups of mammary tumor-bearing rats were studied: i) control non-treated rats, ii) rats treated with HA, iii) rats treated with sTAA. The experiment was terminated when tumors in 70% of the rats became ulcerous. The treatment with sTAA significantly decreased, compared to controls, the yield and total area of the tumors. In rats treated with sTAA, the appearance of new tumors stopped at week 5 as compared to week 7 in rats treated with HA and week 10 in control rats. In rats treated with sTAA, the time of appearance of ulcerous tumors increased to 8 weeks, as compared to 6 weeks in controls and in rats treated with HA. Duration of the experiment increased from 11 weeks in controls to 12 weeks in rats treated with HA and to 14 weeks in rats treated with sTAA. We conclude that sTAA have tumor-suppressive properties, which are well-defined if the treatment is begun on small tumors.
本研究检测了从乳腺癌患者血清中分离出的可溶性66 kDa和51 kDa肿瘤相关抗原（sTAA）与市售人白蛋白相比，对化学诱导的大鼠乳腺肿瘤发生是否具有特异性抑制作用。用二甲基苯蒽（DMBA，10 mg/只大鼠，分两次给药）诱导8周龄的Sprague Dawley大鼠发生乳腺肿瘤。在出现许多大肿瘤后，每周给予sTAA制剂（50 - 60 μg/只大鼠，溶于0.5 ml无菌PBS中）或市售人白蛋白（HA，剂量与sTAA相同），持续10 - 14周。对以下几组荷乳腺肿瘤大鼠进行了研究：i）未治疗的对照大鼠；ii）用HA治疗的大鼠；iii）用sTAA治疗的大鼠。当70%的大鼠肿瘤出现溃疡时终止实验。与对照组相比，sTAA治疗显著降低了肿瘤的产量和总面积。在用sTAA治疗的大鼠中，新肿瘤在第5周停止出现，而用HA治疗的大鼠在第7周，对照大鼠在第10周新肿瘤仍在出现。在用sTAA治疗的大鼠中，出现溃疡肿瘤的时间增加到8周，而对照组和用HA治疗的大鼠为6周。实验持续时间从对照组的11周增加到用HA治疗的大鼠的12周，以及用sTAA治疗的大鼠的14周。我们得出结论，sTAA具有肿瘤抑制特性，如果在小肿瘤阶段开始治疗，其特性会更加明确。
